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Abstract: Recently, several new ophthalmic NSAID products have been introduced for 
commercial use in the United States. The purpose of this review is to brieﬂ  y overview the 
ophthalmic NSAIDs currently in use and to discuss the management of postoperative ocular 
inﬂ  ammation and pain following cataract surgery with a particular focus on bromfenac ophthalmic 
solution 0.09%. Bromfenac ophthalmic solution 0.09% is indicated for the reduction of ocular 
pain and inﬂ  ammation following cataract surgery. Studies have shown that bromfenac ophthalmic 
solution 0.09% has equivalent efﬁ  cacy to the other topical NSAIDs in reducing postsurgical 
inﬂ  ammation and controlling pain. The unique chemical structure of bromfenac makes it both a 
potent inhibitor of the COX-2 enzyme and a highly lipophilic molecule that rapidly penetrates to 
produce early and sustained drug levels in all ocular tissues. Clinically, these pharmacokinetic 
features are manifested in a rapid reduction of postsurgical inﬂ  ammation and pain with bid 
dosing. Bromfenac ophthalmic solution 0.09% is a versatile agent and is effective when used 
as either monotherapy or as an adjunct therapy to steroids.
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Overview of postoperative ocular inﬂ  ammation
In ocular tissue, arachidonic acid is metabolized by cyclooxygenase (COX) to 
prostaglandins which are the most important lipid-derived mediators of inﬂ  ammation.1 
Ocular inﬂ  ammation is characterized by redness, swelling, and/or pain associated with 
irritation or trauma to the eye. Surgical trauma causes a trigger of the arachidonic 
acid cascade which in turn generates prostaglandins (PG) by activation of COX-1 and 
COX-2. Phospholipids in the cell membrane are the substrate for phospholipase A to 
generate arachidonic acid from which a family of chemically distinct prostaglandins 
and leukotrienes are produced.2 Clinical symptoms of prostaglandin production include 
hyperemia, miosis, impaired vision, pain, and diminished visual acuity secondary to 
cystoid macular edema (CME).3
Ocular actions of prostaglandins are manifested in three ways.4 Firstly, they act 
on intraocular pressure (IOP). Prostaglandin E1 (PGE1) and prostaglandin E2 (PGE2) 
increase the IOP by local vasodilation and increased permeability of the blood–aqueous 
barrier. Conversely, prostaglandin F2-α (PGF2-α) lowers the IOP which is attributed to 
increased uveoscleral outﬂ  ow. Secondly, they act on iris smooth muscle to cause miosis. 
Thirdly, prostaglandins cause vasodilation and increase the vascular permeability 
resulting in increased aqueous humor protein concentration.4
Prostaglandin synthesis can be reduced by inhibiting phospholipase A2, which 
inhibits the release of arachidonic acid from cell membrane phospholipids, or by inhibit-
ing the conversion of arachidonic acid to prostaglandins via the COX pathway. Different 
classes of anti-inﬂ  ammatory medications may block different portions of this pathway. Clinical Ophthalmology 2009:3 200
Cho et al
Corticosteroids interfere with the activity of phospholipase 
A2, thereby inhibiting the release of arachidonic acid and 
the production of all arachidonic acid metabolites, including 
prostaglandins.5 In constrast, nonsteroidal anti-inﬂ  ammatory 
drugs (NSAIDs) nonspeciﬁ  cally and irreversibly inhibit the 
synthesis of prostaglandins by interfering with the activity 
of COX-1 and COX-2 (Figure 1).5
There are 2 important isoforms of COX. COX-1 is an 
enzyme that is expressed constitutively in almost all tissues, 
particularly in the gastrointestinal tract, platelets, endothelial 
cells, and kidney.6 COX-1 is responsible for the production 
of prostaglandin G2 (PGG2), which is important for homeo-
static functions, such as maintaining the integrity of the 
gastrointestinal mucosa, mediating platelet function, and 
regulating renal blood ﬂ  ow.7 The expression of COX-2 occurs 
in response to the exposure to a noxious stimulus. It has been 
demonstrated in rats that COX-2 is the primary mediator 
for ocular inﬂ  ammation.8 Therefore, inhibition of COX-2 is 
thought to be the most important therapeutic mechanism of 
ophthalmic NSAIDs.
As described above, the two main treatments for ocular 
inﬂ  ammation are topical corticosteroids or NSAIDs. The 
corticosteroids, which are considered the gold standard 
for the treatment of ocular inﬂ  ammation, are associated 
with an increased incidence of adverse events that warrant 
their judicious use.3 These adverse events include cataract 
formation, a rise in IOP, increased susceptibility to microbial 
infections due to a suppressed host immune response 
and retardation in corneal epithelial and stromal wound 
healing.9 Steroids may not be safe for periods of extended 
use, as prolonged use is associated with the development of 
glaucoma, visual acuity defects and loss of visual ﬁ  eld, and 
posterior subcapsular cataract formation.3 Cataract surgeons 
have therefore been interested in alternative treatments for 
postoperative pain and inﬂ  ammation with effectiveness 
equivalent to steroids but with fewer complications.
Classiﬁ  cation of NSAIDs
A safer alternative to corticosteroids for the treatment of 
ocular inﬂ  ammation are the NSAIDs. NSAIDs comprise 
several chemically heterogeneous classes of drugs which 
possess potent COX inhibitory activity. Topical NSAIDs 
are classified into six groups based on their chemical 
composition: indoles, phenylacetic acids, phenylalkanoic 
acids, salicylates, fenamates, and pyrazolones. Salicylates, 
fenamates, and pyrazolones are considered too toxic to be 
used in the eye.10,11 Most of the NSAIDs are weakly acidic 
drugs, which ionize at the pH of the lacrimal ﬂ  uid and there-
fore have limited permeability through the anionic cornea 
which has an isoelectric point pI of 3.2.12 Reducing the pH 
of the formulation increases the unionized fraction of the 
drug which enhances permeation. Being acidic, NSAIDs 
are inherently irritant, and reducing the pH of formulation 
further increases their irritation potential, and decreases 
their aqueous solubility.13 In addition, the anionic nature 
of NSAIDs lends to the formation of insoluble complexes 
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Figure 1 Prostaglandin and thromboxan biosynthesis.   After FitzGerald and Patrono 2001.84
Abbreviations: COX, cyclooxygenase; coxibs, COX-2 inhibitors; PG, prostaglandin; TxA2, thromboxane A2; NSAID, nonsteroidal anti-inﬂ  ammatory drug; ASA, aspirin.Clinical Ophthalmology 2009:3 201
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with cationic quaternary ammonium preservatives, such as 
benzalkonium chloride.14,15 Thus, it has proved difﬁ  cult to 
formulate topical NSAID formulations that are comfortable 
when applied topically to the eye.
Four topical ocular NSAIDS are currently approved by the 
US Food and Drug Administration (FDA) for the treatment 
of postoperative inﬂ  ammation after cataract surgery. They 
are diclofenac sodium ophthalmic solution 0.1% (Voltaren®, 
Novartis),16 ketorolac tromethamine ophthalmic solution 
0.5% (Acular®, Allergan),17 nepafenac ophthalmic suspension 
0.1% (Nevanac®, Alcon)18 and bromfenac ophthalmic 
solution 0.09% (Xibrom®, Ista).19 The FDA approved dosing 
for diclofenac and keterolac is 4 times daily. Nepafenac is 
FDA approved for a thrice-daily dosing regimen beginning 
1 day before cataract surgery. The FDA approved dosing for 
bromfenac is twice daily, with no predosing before surgery 
necessary (Table 1).16–19
Ophthalmic NSAIDs currently play 4 principal roles in 
ophthalmic surgery, including the prevention of intraopera-
tive miosis during cataract surgery, management of postop-
erative inﬂ  ammation, the reduction of pain and discomfort 
after cataract and refractive surgery, and the prevention and 
treatment of cystoid macular edema (CME) after cataract 
surgery.2,20,21
Studies comparing NSAIDs with corticosteroids 
have demonstrated no signiﬁ  cant difference in the results 
between these treatments.11,22,23 However, NSAID treatment 
appears to be more effective than topical corticosteroids in 
re-establishing the blood–aqueous barrier.22,24 Many studies 
that analyzed the effects of NSAIDs on postoperative 
inﬂ  ammation included the concurrent administration of 
corticosteroids, suggesting that NSAIDs and corticosteroids 
have the potential for synergistic activities.21,24,25 The 
beneﬁ  cial effects of NSAIDs over corticosteroids include 
stabilization of IOP, provision of analgesia and reduction 
of the risk of secondary infections.26
Introduction to bromfenac
Bromfenac sodium ophthalmic solution 0.1% was first 
approved in May 2000 as Bronuck® (Senju Pharmaceutical 
Company, Ltd., Osaka, Japan) and is presently approved by 
the Ministry of Health in Japan for the clinical indications 
of the treatment of postoperative inﬂ  ammation, blepharitis, 
conjunctivitis, and scleritis.19 The same formulation was 
approved by the FDA in March 2005 as Xibrom® (bromfenac 
ophthalmic solution 0.09%). Bromfenac ophthalmic solution 
0.09% is indicated for the treatment of postoperative inﬂ  am-
mation in patients who have undergone cataract extraction. 
The recommended dosage of bromfenac ophthalmic solution 
0.09% is one drop in the affected eye(s) twice daily beginning 
24 hours after cataract surgery and continuing through the 
ﬁ  rst 2 weeks of the postoperative period.19
Pharmacology of bromfenac
Chemistry
Bromfenac sodium is designated chemically as sodium 
2-amino-3-(4-bromobenzoyl) phenylacetate sesquihydrate, with 
an empirical formula of C15H11BrNNaO3⋅1 ½ H20. The structural 
formula for bromfenac sodium is shown in Figure 2.
Nepafenac (Figure 3) unlike other topical NSAIDs, is 
not a free acid. Rather, it is an NSAID prodrug, a property 
that allows it to rapidly cross the cornea. In vitro, nepafenac 
permeates the human cornea 6 times faster than diclofenac.27 
After penetrating the cornea, nepafenac undergoes rapid 
bioactivation to amfenac in ocular tissues (Figure 3).27 The 
structure of bromfenac is identical to amfenac, with the key 
exception of a bromine atom at the C4 position.28,29,30 The 
addition of the bromine imparts three important characteristics 
to the bromfenac molecule to distinguish it from other 
NSAIDs. First, bromine enhances the lipophilicity of the 
molecule and facilitates its penetration through the cell mem-
brane of various tissues, including ocular tissues, which in 
turn gives increased duration of action and enhanced COX-2 
inhibitory activity.29,30 The commercially available formula-
tion is buffered to a pH of 8.3 and contains polysorbate 80 as 
solubilizer and benzalkonium chloride (0.005%) as preser-
vative.1 Second, bromination in the 4 position of the phenyl 
ring increases the duration of analgesic and antiinﬂ  ammatory 
activity.28,30 Third, the bromine modiﬁ  cation may result in an 
enhanced inhibitory effect on COX-2.
Table 1 Commercially available topical NSAIDs indicated for pain and inﬂ  ammation associated with cataract surgery16–19
Generic Brand Manufacturer Chemical class Formulation
Ketorolac Acular Allergan Phenylalkanoic acid 0.5% solution
Diclofenac Voltaren Novartis Phenylacetic acid 0.1% solution
Nepafenac Nevanac Alcon Arylacetic acid 0.1% suspension
Bromfenac Xibrom Bausch and Lomb Phenylacetic acid 0.09% solutionClinical Ophthalmology 2009:3 202
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Pharmacokinetics
NSAIDs vary in their relative potency against COX-1 
and COX-2. Although the exact plasma concentration of 
bromfenac following ocular administration is unknown, the 
relative potency is assessed by determining the concentration 
of drug required to inhibit the COX enzyme activity by 50% 
(inhibitory concentration 50% or IC50). A smaller IC50 value 
signiﬁ  es greater inhibition of the enzyme.7 In vitro studies 
have shown that the inhibitory effects of bromfenac on 
COX-2 are 3.7 times greater than those of diclofenac,31 6.5 
times greater than those of amfenac,32 and 18 times more 
potent than those of ketorolac (Tables 2 and 3).33 The COX-2 
puriﬁ  ed from rabbit alveolar macrophage was used for the 
COX-2 enzyme inhibition assay of bromfenac, diclofenac, 
and amfenac.31,33 In another study involving arachidonic 
acid and carrageenan-induced conjunctival edema in rabbits, 
bromfenac was found to be 3.8 and 10.9 times more potent 
than indomethacin and pranoprofen as an inhibitor of 
prostaglandin production.34 It is important to keep in mind, 
however, that studies examining relative inhibitory COX 
activity of NSAIDs often utilize differing protocols and 
enzyme sources. Therefore, the comparative assessment of 
NSAID IC50 is not directly correlated with clinical indicators 
of therapeutic effectiveness.
Pharmacokinetic studies of bromfenac on animals
Two animal studies have demonstrated that bromfenac 
ophthalmic solution rapidly achieves measurable levels in all 
major ocular tissues and that detectable levels are sustained 
over 24 hours. First, Bakalyan and colleagues35 examined the 
distribution of a single application of radiolabeled bromfenac 
ophthalmic solution in New Zealand White Rabbit eyes. 
After the administration of 50 μL of C-bromfenac sodium 
ophthalmic solution to the right eyes of 14 randomly assigned 
animals, samples of the cornea, aqueous humor, iris/ciliary 
body, choroid, and retina were collected at multiple time 
points for analysis. Peak concentrations of radiolabeled 
bromfenac were observed in the aqueous humor and most of 
the ocular tissues at 2 hours. Concentrations were highest in 
the cornea and bromfenac was detected in all samples over 
24 hours.35 By comparison, in a separate but similar evalua-
tion of C-nepafenac with 3 times the commercially available 
dose, initial penetration into ocular tissues produced detect-
able drug levels in the cornea and iris/ciliary body beyond 
24 hours but not in the aqueous humor or choroid beyond 
12 hours and in the retina beyond 6 hours.36
Second, McNamara and associates37 recently replicated 
Bakalyan’s results with a single drop of bromfenac. In the 
same animal model, peak concentrations of C-bromfenac 
were observed at or before 2 hours with measurable levels 
in all ophthalmic tissues, including the retina, over 24 hours, 
after a single ophthalmic dose. Although the clinical signiﬁ  -
cance of these animal studies is unknown, the data suggest 
that because bromfenac ophthalmic solution rapidly reaches 
sustained concentrations in all ocular tissues, it may ﬁ  nd 
utility in treating disorders associated with inﬂ  ammation in 
other ocular tissues.7
Clinical studies of bromfenac 
ophthalmic solution
Clinical studies to date have shown mixed results on which 
topical NSAIDs are the most effective.
Pharmacokinetic studies of bromfenac 
on dosing
Ogawa and colleagues34 evaluated the pharmacokinetic 
proﬁ  le of bromfenac ophthalmic solution 0.09% in human 
subjects undergoing cataract surgery, in part to validate 
the sufﬁ  ciency of bid dosing. A single drop of bromfenac 
ophthalmic solution at the commercial concentration was 
administered to 54 subjects at a variety of speciﬁ  ed time 
points before cataract surgery. At the start of each case, 
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100 μL of aqueous humor was extracted for analysis. The 
results showed rapid absorption (within 15 minutes) with the 
peak aqueous humor concentration of bromfenac occurring 
at 150 and 180 minutes after instillation.34 This study showed 
effective concentrations in the aqueous humor persisting for 
12 hours after a single application, which suggests that bid 
dosing is sufﬁ  cient to maintain anti-inﬂ  ammatory efﬁ  cacy.
Optimal concentration of bromfenac
Masuda and colleagues performed a multicenter, phase 
2 clinical study evaluating the optimal concentration of 
the ophthalmic solution of twice-daily 0.01%, 0.1%, and 
0.2% bromfenac drops in 228 cataract cases. The 0.1% and 
0.2% groups showed superior anti-inﬂ  ammatory activity, 
and although adverse events did not seem concentration 
dependent, the 0.1% concentration was deemed optimal to 
minimize any potential for corneal toxicity.38
Pharmacodynamics of bromfenac 
vs nepafenac/amfenac vs ketorolac
Walters et al39 researched the in vivo pharmacokinetics and 
in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, 
and bromfenac in 5 private ophthalmology practices through-
out the United States. Patients requiring cataract extraction 
were randomized to 1 of 3 treatment groups: nepafenac, 
ketorolac, or bromfenac. Patients were administered 1 drop 
of the test drug before cataract surgery and an aqueous humor 
sample was collected during paracentesis and later analyzed 
for drug concentration. In addition, COX-1 and COX-2 
inhibitory activities were determined via the in vitro measure-
ment of PGE2 inhibition. Seventy-ﬁ  ve patients participated in 
this study and Walters et al determined that nepafenac showed 
signiﬁ  cantly greater ocular bioavailability and greater potent 
COX-1 inhibition than any other drug tested and amfenac 
demonstrated greater potency and COX-2 inhibition than 
ketorolac or bromfenac.39
PGE2 inhibition of bromfenac vs ketorolac
Bucci et al40 compared aqueous drug concentrations and PGE2 
levels in patients treated with ketorolac 0.4% and bromfenac 
0.09% at trough dosing and found that higher aqueous levels 
(130.5 + 37.8 ng/mL and 6.2 + 3.1 ng/mL) and greater PGE2 
inhibition (204.2 pg/mL + 95.5 [SD] vs 263.7 + 90.0) were 
observed in cataract surgery patients treated with ketorolac 
0.4% than in patients treated with bromfenac 0.09% at 
trough dosing, suggesting that ketorolac 0.4% may provide 
better control of prostaglandin-mediated inﬂ  ammation than 
bromfenac 0.09% administered twice a day.
COX inhibition of bromfenac vs ketorolac
Another study analyzing NSAID COX inhibitory activities 
compared the COX inhibitory activity and ocular anti-
inﬂ  ammatory effects of ketorolac and bromfenac.32 The 
authors reported that ketorolac inhibited COX-1 more 
strongly than bromfenac while bromfenac had greater COX-2 
inhibitory activity than ketorolac. A similar relationship was 
also found in the Walters study,39 which validates the results 
of Waterbury et al.32
Bromfenac vs diclofenac ophthalmic 
solution
Several subsequent clinical studies have compared the 
efﬁ  cacy of bromfenac ophthalmic solution with diclofenac 
ophthalmic solution in reducing inﬂ  ammation after cataract 
surgery.41–43
Prospective, single-center randomized trial
Kawaguchi and associates41 found that bromfenac has a more 
rapid onset of anti-inﬂ  ammatory activity than diclofenac 
based upon a prospective, single-center, randomized trial 
in 38 subjects (49 eyes) who underwent cataract surgery. 
Measuring aqueous ﬂ  are levels, the group noted that at each 
time point, ﬂ  are was lower in the bromfenac group than in the 
diclofenac group, a difference that was statistically signiﬁ  cant 
during the ﬁ  rst 2 weeks of surgery (p  0.05).41
Retrospective/prospective analysis
Takamatsu et al42 found that bromfenac ophthalmic solu-
tion exerted anti-inﬂ  ammatory effects that were compa-
rable to or greater than diclofenac ophthalmic solution, 
including comparable suppression of CME and posterior 
Table 2 Relative potency of bromfenac, diclofenac, and amfenac in 
vitro: IC50 values of cyclooxygenase-2 (COX-2)7,31,33
IC50 COX-2 (nM)
Bromfenac 23
Diclofenac 85
Amfenac 150
Table 3 Relative potency of bromfenac and ketorolac in vitro: IC50 
values of cyclooxygenase-2 (COX-2)7,32
IC50 COX-2 (nM)
Bromfenac 6.6
Ketorolac 120Clinical Ophthalmology 2009:3 204
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capsule opaciﬁ  cation. Of clinical importance, bromfenac 
was associated with less corneal epitheliopathy than diclof-
enac. Subjects at 2 facilities were divided into bromfenac 
and diclofenac treatment groups after uncomplicated cata-
ract surgery. A retrospective analysis of data from the ﬁ  rst 
facility included a total of 228 eyes from 157 subjects, 
whereas a prospective analysis from the second facility 
included a total of 58 eyes from 30 subjects. Early dif-
ferences in the ﬂ  are level seen between the two treatment 
arms disappeared by the 28th postoperative day. However, 
the incidence of corneal epitheliopathy was signiﬁ  cantly 
higher in the diclofenac group in the ﬁ  rst center, despite tid 
dosing in both arms.42
Multicenter, open-label clinical study
Ohara and associates43 also compared the effects of 
bromfenac ophthalmic solution with diclofenac ophthalmic 
solution on postoperative inﬂ  ammation after cataract phaco-
emulsifcaition and intraocular lens implantation. Their 
multicenter, open-label, clinical study divided 111 subjects 
into 2 treatment groups, each of which received 2 drops of 
bromfenac or diclofenac preoperatively, and then bromfenac 
bid or diclofenac tid with concomitant ophthalmic steroid and 
anti-infective for 4 weeks, beginning the day after surgery. 
Anterior chamber cells and ﬂ  are and corneal epithelial 
disorder in the two groups showed no statistically signiﬁ  cant 
difference after day 7.43
Phase III trials
Two phase 3 clinical trials were performed in the United 
States to evaluate the efficacy, safety, and tolerability 
of bromfenac ophthalmic solution 0.09% in treating 
postoperative inﬂ  ammation and pain after cataract surgery. 
The study consisted of 2 randomized, double-masked, 
placebo-controlled United States trials in which subjects 
with a summed ocular inﬂ  ammation score (SOIS = anterior 
chamber cell score plus ﬂ  are score, each on a scale of 0–4) 
of 3 after cataract surgery were assigned to bromfenac 
or placebo in a 2:1 ratio following surgery. Subjects self-
instilled 1 drop of the assigned test agent twice daily for 
14 days and were followed for an additional 14 days for safety 
evaluation. The primary endpoint was reduction of ocular 
inﬂ  ammation assessed 14 days after surgery using a slit 
lamp binocular microscope. Subjects were excluded if they 
used any ocular, topical, or systemic medication that could 
interfere with normal lacrimation, wound healing, the test 
agent, or the interpretation of study results within 1 week of 
study visit 1.44 This study had no pretreatment, no ophthalmic 
corticosteroid use, and included only subjects with moderate 
to severe ocular inﬂ  ammation after cataract surgery.
In the intent-to-treat analyses of both studies, a signiﬁ  cant 
effect of bromfenac on ocular inﬂ  ammation after cataract 
surgery was demonstrated (62%–66% vs 40%–48%; 
p  0.0001). These results demonstrate that bromfenac 
ophthalmic solution 0.09% dosed twice a day for 14 days 
was effective for the reduction of ocular inﬂ  ammation (to 
trace or cleared). Although the primary efﬁ  cacy endpoint 
was a reduction of inﬂ  ammation to trace or cleared cells 
and no ﬂ  are, there was an additional assessment of marked 
improvement in inﬂ  ammation. Findings of conjunctival 
erythema, conjunctival edema, and ciliary ﬂ  ush in bimicro-
socpy examinations were signiﬁ  cantly better for subjects 
treated with bromfenac, supporting the efﬁ  cacy of bromfenac 
ophthalmic solution 0.09% in reducing inﬂ  ammation after 
cataract surgery. CME was reported as an adverse event 
for 1.4% of the subjects in the bromfenac group, compared 
with 4.7% (p  0.05) in the vehicle group, suggesting that 
bromfenac treatment may have reduced the incidence of this 
important potential complication of cataract surgery.44
Bromfenac ophthalmic solution 0.09% was effective 
for the rapid resolution of ocular pain after cataract surgery. 
There was a statistically signiﬁ  cant difference between 
the bromfenac and placebo groups demonstrated in these 
phase III clinical trials. Median time to resolution of ocular 
pain was 2 days with bromfenac, vs 5 days with a placebo 
(p  0.0001).44 There are 2 very important aspects of the 
design of these clinical trials which distinguish them from 
previous ophthalmic studies.44 First, no predosing of the 
agent or concomitant steroid use was permitted before 
randomization into the clinical study. Second, the degree 
of ocular inﬂ  ammation at entry into the clinical trial was 
moderate to severe. In a separate clinical trial with ketorolac, 
statistical signiﬁ  cance for ocular pain was not reached until 
visit days 14 to 16 (p = 0.049).20
Safety and tolerability of bromfenac 
ophthalmic solution
Signiﬁ  cant adverse effects have been associated with the use 
of systemic NSAIDs.45 Diclofenac induced hepatotoxicity has 
been well characterized46,47 and ketorolac has been associ-
ated with gastrointestinal, renal, and hematologic adverse 
reactions and 143 deaths by 1993.48 Subjects in clinical 
trials of long-term treatment with the oral bromfenac,28,29 
were found to have an increased incidence of liver enzyme 
elevations. While there were no cases of serious liver injury, 
the FDA prescribing information for oral bromfenac was Clinical Ophthalmology 2009:3 205
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subsequently amended to include a re-emphasized “black 
box” warning limiting use to no more than 10 days. In a 
rabbit model of ocular inﬂ  ammation, effects of bromfenac 
were observed in the contralateral eye, suggesting possible 
systemic effects.49
Adverse effects of bromfenac
The most common adverse events reported with bromfenac 
included abnormal sensation in the eye, conjunctival 
hyperemia, eye irritation (including burning/stinging), eye 
pain, eye pruritis, eye redness, headache, and iritis. These 
events were reported in 2% to 7% of patients (Table 4).
No deaths have been reported with bromfenac 0.09% 
ophthalmic solution. In postmarketing surveillance, less 
frequently reported events observed included corneal 
erosion, corneal perforation, corneal thinning, and epithelial 
breakdown. During the two phase III clinical trials described 
above, the ocular adverse events were mild, and occurred less 
frequently with bromfenac than with placebo. A component 
of postsurgery ocular inﬂ  ammation is ocular irritation. The 
rapid onset of bromfenac in the treatment of postsurgical 
inﬂ  ammation diminishes ocular irritation, including burning 
and stinging.50
Bromfenac ophthalmic solution is in Pregnancy 
Category C. Teratogenicity has not been observed in 
animal studies. However, bromfenac was associated with 
embryo-fetal lethality, increased neonatal mortality, and 
reduced postnatal growth at high doses in rats, and increased 
postimplantation losses at high doses in rabbits. Use during 
pregnancy is recommended only if the potential benefit 
justiﬁ  es the potential risk to the fetus. Use should be avoided 
during late pregnancy because of the known effects of 
prostaglandin-inhibiting agents on the fetal cardiovascular 
system (closure of the ductus arteriosus).50
Senju Pharmaceuticals Co, Ltd, has developed bromfenac 
sodium hydrate ophthalmic solution 0.1% as a therapeutic 
for external or anterior ocular inﬂ  ammatory diseases, such as 
blepharitis, conjunctivitis, scleritis, episcleritis, and postoper-
ative ocular inﬂ  ammation.34,41 Results from preclinical studies 
demonstrate that bromfenac ophthalmic solution is noncar-
cinogenic and nonteratogenic, does not accumulate in any 
organ, is cleared rapidly from all tissues, and does not affect 
reproductive performance. There are no known interactions 
of bromfenac with other drugs, whether ophthalmic or 
nonophthalmic, or with medical conditions. Results from 
clinical studies demonstrated no abnormal ﬁ  ndings speciﬁ  c 
to dose concentrations or clinically signiﬁ  cant changes in 
liver chemistries indicative of hepatotoxicity. Bronuck was 
approved by the Ministry of Health, Labour and Welfare of 
Japan in 2000 following the completion of phase III clinical 
trials, and to date, there have been over 10 million patient 
uses.45 For most patients, ophthalmic administration has been 
1 drop daily for 14 days. Reports of serious and nonserious 
adverse effects have been low since drug approval and there 
have been no reports of liver toxicity according to the post-
marketing safety surveillance data available.
The relationship of corneal melts 
with bromfenac ophthalmic solution
Arguably the most serious side effect that has occurred with 
topical NSAID use is corneal melting and ulceration, which 
were reported by Lin et al51 following use of diclofenac 
sodium. Subsequently, other cases of corneal melt follow-
ing the use of diclofenac as well as ketorolac and nepafenac 
have been reported.52–58
Three case reports by Asai et al57 in Japan have been 
published describing corneal melting in patients using 
bromfenac ophthalmic solution. Each of the three cases of 
corneal stromal melting occurred in the setting of 3 common 
factors: pre-existing conditions that predisposed the cornea 
to toxicity, bromfenac use, and oﬂ  oxacin use. None of the 
patients in the report had undergone cataract extraction. One 
patient had been using bromfenac ophthalmic solution for 
40 days. All cases were resolved with conservative treatment 
that included the use of a bandage soft contact lens and/or 
antibiotics and lubrication.
Isawi recently published a case report of bilateral cor-
neal melting and perforation in Stevens Johnson syndrome 
(SJS) following topical bromfenac use for 2 weeks. The tear 
deﬁ  ciency in this SJS patient may have predisposed her to 
Table 4 Common ocular adverse events of xibrom (bromfenac 
ophthalmic solution) 0.09% vs vehicle7,31
Ocular adverse events Bromfenac 0.09% Vehicle
Number 356 (100%) 171 (100%)
Iritis 7.0% 18.1%
Abnormal sensation in eye 6.5% 8.2%
Eye pain 4.2% 11.7%
Eye pruritis 3.9% 2.9%
Posterior capsule opaciﬁ  cation 3.9% 4.1%
Partial vision loss 3.1% 9.4%
Eye irritation (burning/stinging) 2.5% 4.7%
Eye redness 2.2% 7.6%
Conjunctival hyperemia 2.2% 11.1%
Photophobia 2.0% 11.1%Clinical Ophthalmology 2009:3 206
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NSAID-induced epithelial cell healing disturbances, which 
may have led to the corneal melting and perforation.58
It is important to note that in the three cases reported 
by Asai,57 2 of the patients had severe ocular surface 
compromise: a 58-year-old with Fuchs’ dystrophy-induced 
bullous keratopathy and a patient being treated for a 
bacterial corneal ulcer in 1 eye. Given that previous studies 
have implicated NSAIDs in decreasing corneal epithelium 
migration59 and in delaying wound healing,60 it may be that 
with underlying surface abnormalities, the capacity of the 
corneal epithelium to self-repair may be diminished and thus 
a smaller insult may precipitate a more severe reaction, such 
as corneal melting. These cases highlight the importance of 
being selective when prescribing topical NSAIDs, especially 
in patients with underlying ocular surface abnormalities.
Systemic safety of bromfenac ophthalmic 
solution
Stewart et al45 evaluated the systemic safety of bromfenac 
ophthalmic solution 0.09% vs placebo for the treatment of 
postoperative inﬂ  ammation and reduction of ocular pain in 
subjects who have undergone cataract extraction. The study 
was 2 phase III, multicenter, randomized, double-masked, 
parallel, placebo-controlled clinical trials with data pooled 
for analysis as described above. This study showed that 
bromfenac ophthalmic solution 0.09% dosed twice a day for 
14 days after cataract surgery demonstrated neither treatment-
related systemic adverse events (SAEs) nor evidence of 
hepatic toxicity. No treatment-related serious SAEs occurred 
in either clinical trial, and there was a low occurrence of 
systemic effects overall. The systemic results with bromfenac 
ophthalmic solution reported in this paper support the post-
market clinical experience in Japan where there were no 
reports of systemic drug-related adverse events.61
In contrast, systemic adverse reactions have been reported 
for earlier generations of ophthalmic NSAIDs. Diclofenac 
sodium ophthalmic solution 0.1%, which is currently approved 
by the FDA for postoperative inﬂ  ammation following cataract 
extraction, was associated with abdominal pain, asthenia, 
chills, dizziness, facial edema, fever, headache, insomnia, 
nausea, pain, rhinitis, viral infection, and vomiting.46 Clinical 
trials of ophthalmic nepafenac (Nevanac®) were associated 
with headache, hypertension, nausea/vomiting, and sinusitis 
in 1% to 4% of subjects from clinical studies. Dosing with the 
topical solution of either diclofenac or ketorolac is 4 times a 
day and nepafenac is dosed 3 times a day. Bromfenac oph-
thalmic solution 0.09% is the only bid ophthalmic NSAID 
approved in the United States. The decreased dosage may 
further limit drug and preservative exposure and minimize 
systemic absorption.45
Tolerability and convenience 
of bromfenac
The twice-daily dosing schedule is convenient for the post-
cataract surgery patient population and may enhance patient 
compliance and adherence to the recommended dosage 
schedule. Multiple clinical studies have shown that patient 
compliance in administering medications, especially in older 
subjects, improve with less frequent dosing.62,63 No other 
ophthalmic NSAID has been approved by the FDA with a 
twice-daily dosing regimen. In contrast to the thrice-daily or 
4 times daily dosing schedules of other ophthalmic NSAIDs, 
the twice-daily dosing schedule reduces drug exposure while 
still maintaining signiﬁ  cant clinical efﬁ  cacy.
There are additional convenience factors for bromfenac 
in comparison to other NSAIDs:44 bromfenac ophthalmic 
solution does not require shaking before administration, 
whereas nepafenac, a suspension, requires shaking before 
each administration; less frequent dosing also means reduced 
exposure to the preservative benzalkonium chloride. The 
level of benzalkonium chloride in bromfenac ophthalmic 
solution 0.09% is 0.005%, the same as in nepafenac 
ophthalmic solution 0.1%. In contrast, the percentage of 
benzalkonium chloride is higher in ketorolac tromethamine 
ophthalmic solution 0.4% (0.006%) and even higher in 
ketorolac tromethamine ophthalmic solution 0.5% (0.01%). 
Higher levels of benzalkonium chloride have been associated 
with corneal epithelial dysfunction.64
Other clinical applications 
of bromfenac
Increasing use of new generation NSAIDs 
in the treatment of CME
Brief overview of CME
Since its ﬁ  rst recognition and description in 1974,65 CME 
has been recognized as the most common cause of decreased 
vision postoperatively in uneventful cataract surgery.66 CME 
is caused by cystic accumulation of intraretinal ﬂ  uid in the 
outer plexiform and inner nuclear layers of the retina, as a 
result of the breakdown of the blood–retinal barrier.67 CME 
can be a serious consequence of numerous ocular procedures 
and conditions, including cataract surgery, ocular inﬂ  am-
matory disease, retinal vascular diseases, and tractional 
disorders.68 It is not a disease itself, rather the endpoint of a 
variety of processes that lead to the accumulation of ﬂ  uid in Clinical Ophthalmology 2009:3 207
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the central retina.69 It can present with symptoms of blurred 
or declined central vision, and painless retinal inﬂ  ammation 
or swelling. Vision loss is usually temporary, with rare 
incidences of permanent visual loss.20 Often, however, 
the condition is often asymptomatic and may be detected 
only with ﬂ  uorescein angiography or optical coherence 
tomography.70 Studies suggest that the rate of clinical CME 
is in the range of 1% to 2%,71 whereas the incidence of 
angiographic CME may be as high as 9% to 19%.72,73
Since inflammation is a known risk factor for the 
development of CME,74 anti-inﬂ  ammatory corticosteroids 
are commonly used to treat this condition, although they 
are associated with serious side effects, including elevated 
IOP and posterior subcapsular cataract.75 Because of this, 
less toxic but equally effective alternatives to corticosteroids 
are desirable.
Although none of the ophthalmic NSAIDs currently 
available in the United States are indicated for the preventitive 
treatment of CME after cataract surgery, topical NSAIDs have 
increasingly been used over the past 2 decades. NSAIDs, 
speciﬁ  cally indomethacin, ﬁ  rst demonstrated efﬁ  cacy for 
the prevention of pseudophakic CME in 1977,76 but it was 
not until much later that ketorolac 0.5% and diclofenac 0.1% 
proved effective in treating this condition.77,78
Prednisolone vs prednisolone/nepafenac 
and the rate of pseudophakic CME
While no randomized trials have yet been conducted to test the 
ability of the two new-generation topical NSAIDs, nepafenac 
and bromfenac, numerous reports suggest that these agents 
also have activity against this condition.79 A study by Wolf 
et al25 compared the incidence of visually signiﬁ  cant pseudo-
phakic macular edema after uneventful phacoemulsiﬁ  cation 
in patients treated postoperatively with topical prednisolone 
and those treated with topical prednisolone and nepafenac 
0.1% suspension and found that those treated with topical 
prednisolone alone had a signiﬁ  cantly higher incidence of 
visually signiﬁ  cant pseudophakic macular edema than those 
treated with topical prednisolone and nepafenac.
Bromfenac vs ketorolac vs diclofenac 
for the treatment of acute pseudophakic CME
Rho et al80 presented results of a study comparing bromfenac 
ophthalmic solution with diclofenac and ketorolac for the 
treatment of acute pseudophaakic CME. Sixty-four eyes 
with documented CME after uncomplicated cataract surgery 
were randomized to receive bromfenac bid, diclofenac qid, 
or ketorolac qid for 3 months. After the treatment period, 
all 3 treatment groups achieved statistically significant 
visual improvement, evaluated by Early Treatment Diabetic 
Retinopathy study letter gained over baseline, and, although 
the differences between the groups were not signiﬁ  cant, there 
was a trend toward signiﬁ  cance for the bromfenac group. Rho 
concluded that twice-daily bromfenac was statistically as 
effective as diclofenac or ketorolac dosed 4 times daily.80
Bromfenac for the prevention 
of miosis during cataract surgery
Some studies suggest that bromfenac ophthalmic solution 
is clinically beneﬁ  cial in a variety of other therapeutic 
and surgical settings that fall outside of the current United 
States-approved indication for bromfenac in the treatment of 
ocular inﬂ  ammation and reduction of ocular pain after cata-
ract extraction.7 The ﬁ  rst use of NSAIDs in ophthalmology 
was for the prevention of miosis during cataract surgery.24 
Ohara and colleagues81 compared bromfenac ophthalmic 
solution with diclofenac ophthalmic solution in an open 
label study of this application. After drop instillation at 60 
and 30 minutes before surgery, pupil diameter and miosis 
rates were evaluated. The investigators concluded that brom-
fenac exerted a comparable antimiotic effect to diclofenac 
and would therefore be useful in suppressing miosis during 
cataract surgery.81
Bromfenac for the treatment 
of allergic conjunctivitis
NSAIDs have been found to be effective for the treatment 
of seasonal allergic conjunctivitis. Bromfenac ophthalmic 
solution was compared with the ophthalmic mast cell 
stabilizer pemirolast potassium for the treatment of seasonal 
allergic conjunctivitis in a clinical study by Miyake Kashima 
et al.82 After bid dosing of each type of drop in the opposite 
eye for 1 week, subjects were evaluated for improvement 
in 5 ocular signs and subjective symptoms. Both drugs 
improved 4 of 5 objective signs but there was no signiﬁ  cant 
difference between the drugs in objective efﬁ  cacy. Neither 
drug signiﬁ  cantly improved subjective symptoms after this 
brief treatment period nor was there any difference between 
them in the subjects’ assessment.82
Bromfenac for the treatment 
of anterior uveitis
Usui and Masude83 reported on the evaluation of twice-daily 
bromfenac ophthalmic solution for the treatment of anterior 
uveitis over both 2-week and 12-week treatment courses. Clinical Ophthalmology 2009:3 208
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The investigators concluded that bromfenac seemed to reduce 
inﬂ  ammation associated with anterior uveitis with minimal 
side effects, potentially providing a safer alternative to long-
term treatment with ophthalmic steroids.
Conclusion
In multiple comparative trials, bromfenac ophthalmic 
solution 0.09% has been shown to provide safe and effective 
relief of perioperative inﬂ  ammation and pain following 
cataract surgery. The unique chemical structure of brom-
fenac makes it both a potent inhibitor of COX-2 enzyme 
and a highly lipophilic molecule that rapidly penetrates to 
produce early and sustained drug levels in all ocular tissues. 
Clinically, these pharmacokinetic features are manifested in 
a rapid reduction of postsurgical inﬂ  ammation and pain with 
bid dosing.7 Bromfenac also has an extensive safety record 
with over 10 million ophthalmic uses globally. Further 
clinical investigations will explore the expanding use of 
bromfenac in a variety of other clinical settings, including, 
but not limited to, the management of ocular inﬂ  ammation 
and pain following cataract surgery.
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